Sign up to save your podcasts
Or
Share The Fellow on Call: The Heme/Onc Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Fellow on Call: The Heme/Onc Podcast
The Fellow on Call: The Heme/Onc Podcast episodes
- Episode 127: Testicular Cancer Series, Pt 1 - Introduction
It’s time for another new series, this time focusing on Testicular Cancer. In this first episode, we lay the foundation for our future discussions and discuss the basics of Testicular Cancer.
Episode contents:
- What are germ cell tumors?
- What are important tumor markers to monitor for germ cell tumors?
- Seminoma vs. Non-seminoma
- Staging of germ cell tumors
- Overview of management
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
29 min - Episode 126: AML Series, Pt 12 - Treatment of patients with relapsed/refractory disease
This week, we round out our AML series with a detailed discussion about the approach to management of relapsed and refractory disease. This has been a VERY long road going through all management of AML. We hope that you have continued to build on our discussions week-to-week. An exciting treatment paradigm that is ever-evolving!
Episode contents:
- How do we define primary induction failure in AML?
- What are options for treatment of refractory disease? What is the mechanism of action of these treatment options?
- What are options for relapsed disease?
- What targeted therapies are available for relapsed AML?
****This episode is sponsored by our global research partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
33 min - Episode 125: AML Series, Pt 11 - Treatment of patients unfit for intensive therapy
In today’s episode, we discuss how to approach AML treatment for patients who are unfit for intensive therapy.
Episode contents:
- How do we assess fitness for intensive AML?
- What are options for patients who are unfit for intensive chemotherapy for AML?
- What are important genetic mutations are important to check for?
- What are the key trials that inform our management in this space?
- How do we dose venetoclax?
- How do we sequence the available agents?
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
33 min - Episode 124: AML Series, Pt 10 - Allogeneic transplant for AML
In today’s episode, we welcome back Dr. Amar Kelkar for part 2 of our two-part discussion on allogeneic transplant. In this episode, we build on our prior discussion regarding transplant, this time focusing on transplant for the treatment of AML.
Episode contents:
- What are the different conditioning regimens available?
- How do we decide which regimen is optimal for our patients?
- What is the role of MRD testing?
- What is the role of maintenance therapy post-transplant?
- What are treatment options for GVHD?
- A discussion on racial disparities in transplant
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
27 min - Episode 123: AML Series, Pt 9 - Introduction to Allogeneic Transplant
In today’s episode, we welcome back Dr. Amar Kelkar for part 1 of our two-part discussion on allogeneic transplant. In this episode, we discuss the fundamental approach to patient selection and stem cell source selection. As you all know from this series, allogeneic transplants play a pivotal role in the management of AML. Dr. Kelkar’s pearls of wisdom help make this confusing topic so much more approachable!
Episode contents:
- What factors do we incorporate when considering a patient for allogeneic transplant?
- How do we use HLA-matching?
- What are the pros and cons of the different sources of stem cells?
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
27 min - Episode 122: AML Series, Pt 8 - AML Maintenance Therapies
This week, we continue our series focusing on acute myeloid leukemia. In this episode, we talk about maintenance therapies in AML.
Episode contents:
- A recap of cytarabine consolidation
- Why do we do maintenance therapy?
- What are hypomethylating agents and how do they work?
- Important targeted agents that play a role in maintenance therapy
****This episode is sponsored by our Global Research Partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
34 min - Episode 121: AML Series, Pt 7 - AML Consolidation: Role of Allogeneic Transplant
This week, we continue our discussion on consolidation and maintenance therapies for AML, this time highlighting the role of allogeneic stem cell transplants. This episode builds on our prior episode, so if you have not listened to this just yet, we highly recommend doing so!
Episode contents:
- A recap on approach to AML consolidation
- The role of allogeneic transplants
- The role of MRD testing in AML management
****Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
25 min - Episode 120: AML Series, Pt 6 - AML Consolidation: Therapeutic Approaches
This week, we move to our next phases of therapy for AML, which are consolidation and maintenance. Be sure to check out our prior episodes for a discussion on initial workup and how we incorporate recurrent genetic abnormalities into how we think about AML. Check out figure 1 from this paper for a helpful diagram!
Episode contents:
- A recap on approach to AML treatment
- Who do we consider for allogeneic transplant?
- What are common therapy-related AML cytogenetic abnormalities to be aware of?
- How do we approach consolidation? Role of G-CSF?
****Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
33 min - Episode 119: AML Series, Pt 5 - AML Induction: Options for Upfront Therapy
This week, we round out our discussion regarding AML induction, this time focusing on the treatment options in the first line setting. We go through the various options, the dosing strategies, and the data behind them.
Be sure to check out parts one and two of this three-part induction discussion, as we continue to build on these concepts! Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation!
Episode contents:
- What are our options for upfront induction therapy?
- How do we select patients for the "add-ons" to induction therapy?
- What is the data behind these options?
****This episode is sponsored by our Global Research Partners! Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
27 min - Episode 118: AML Series, Pt. 4 - AML Induction: Approach to Initial Management
In this week’s episode, we continue onto part two of our three-part discussion on AML induction, this week focusing on selecting our up-front regimen.
Be sure to check out last week’s episode, as this one builds on that one. Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation!
Episode contents:
- What is "7+3"?
- How do we pick our approach to management?
- Do we ever add anything else to our induction back bone?
****Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
26 min
About The Fellow on Call: The Heme/Onc Podcast
From the publisher's feed
We quickly realized we knew very little about hematology and oncology when we started fellowship. Our goal is to bring you the fundamentals, core concepts and important management approaches in our field, driven by the latest evidence and expert opinion. In each episode, we will provide bite-sized, simplified approaches to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to advanced practice providers and practicing physicians.
Best of The Fellow on Call: The Heme/Onc Podcast
Ranked by our users in the last 21 days